Bournemouth, UK, 2nd March 2020 / Sciad Newswire / Solentim, the global leader in cell line development instrumentation, today announced that Dr Mark Truesdale has been appointed to the position of CEO. Mark joined Solentim in October 2019 as Chief Marketing Officer. As CEO, Mark will work with the Company founders and executive team to deliver and execute a strategic growth plan for the business, building on the commercial success and brand strength the company has achieved to-date.
Mark has over 20 years’ experience in life science, most recently seven years at Thermo Fisher Scientific, during which time he held the position of Senior Director of Global Marketing for its Food Protection Business, leading the business unit strategy, product management and tactical marketing teams. Prior to this, Mark spent 14 years with Genetix in a number of roles, including Head of Global Marketing, supporting the Company through its acquisition by Danaher Corporation. Mark holds a BSc in Biochemistry and PhD in Molecular Genetics from the University of London.
Dr Truesdale commented, “I am delighted and honoured to take up the position of CEO for Solentim. In my time with the company I have seen the enormous potential for growth the business has, built on the strong foundation established by the leadership team. I look forward to leading this next phase of the company’s growth.”
Aaron Figg, Co-founder, commented, “2020 marks ten years since Solentim was founded and in that time we have helped hundreds of customers all over the world speed up their cell line development processes, making a tangible contribution to hundreds of new biotherapeutic drug development programmes. By appointing Mark as CEO, Solentim is well placed to build on this success and deliver enhanced solutions to meet the needs of drug development customers over the next ten years.”
For further information, contact:
Dr Mark Truesdale, CEO
T: +44 (0)1202 798510
Media Relations – Sciad Communications
Emma Pickup / Juliette Craggs
T: +44 (0)20 3405 7892
Notes to editors
Solentim is the global leader in enabling accelerated cell line development for new biologic drugs through its proprietary intelligent automation. Solentim’s portfolio of products (VIPS™, Cell Metric® and Cell Metric® CLD) enables customers to establish a simple to use and completely integrated workflow, revolutionising single cell cloning and providing documented daily whole well image assurance of monoclonality for FDA and other regulatory bodies. Solentim works with most of the world’s top 10 pharmaceutical companies and has a customer installed base of several hundred instruments. It also has established strategic partnerships with ATUM and Valitacell. In 2018, Solentim was the recipient of two highly prestigious Queen’s Awards and named in the Deloitte UK Technology Fast 50. Visit www.solentim.com for more information.